[go: up one dir, main page]

MX9706827A - Activacion de receptor por gas6. - Google Patents

Activacion de receptor por gas6.

Info

Publication number
MX9706827A
MX9706827A MX9706827A MX9706827A MX9706827A MX 9706827 A MX9706827 A MX 9706827A MX 9706827 A MX9706827 A MX 9706827A MX 9706827 A MX9706827 A MX 9706827A MX 9706827 A MX9706827 A MX 9706827A
Authority
MX
Mexico
Prior art keywords
gas6
cells
rse
polypeptide
mer receptor
Prior art date
Application number
MX9706827A
Other languages
English (en)
Inventor
Jian Chen
R Glenn Hammonds
Paul J Godowski
Melanie R Mark
Jennie P Mather
Ronghao Li
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/402,253 external-priority patent/US6211142B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX9706827A publication Critical patent/MX9706827A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se ha identificado un activador de las proteínas receptoras Rse y Mer de tirosina cinasas. El activador es codificado por el gen específico de supresion de crecimiento 6 (gas6). En consecuencia, la invencion proporciona un método para activar el receptor de Rse o Mer utilizando el polipéptido gas6. Además, la invencion proporciona un método para mejorar la supervivencia, proliferacion y diferenciacion de células que tienen el receptor Rse o Mer incorporando en sus membranas celulares lo cual involucra a estas células con el polipéptido gas6. Los tipos de células los cuales pueden ser tratados de acuerdo con el método incluyen células de la glia tales como células de Schwann y células mononucleares. Se proporcionan adicionalmente equipos y artículos de fabricacion los cuales incluyen al polipéptido gas6. La invencion también se relaciona con variantes de gas6.
MX9706827A 1995-03-10 1996-03-05 Activacion de receptor por gas6. MX9706827A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/402,253 US6211142B1 (en) 1995-03-10 1995-03-10 Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US43886195A 1995-05-10 1995-05-10
PCT/US1996/003031 WO1996028548A1 (en) 1995-03-10 1996-03-05 Receptor activation by gas6

Publications (1)

Publication Number Publication Date
MX9706827A true MX9706827A (es) 1997-11-29

Family

ID=27017784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706827A MX9706827A (es) 1995-03-10 1996-03-05 Activacion de receptor por gas6.

Country Status (11)

Country Link
US (1) US6169070B1 (es)
EP (1) EP0815224B1 (es)
JP (1) JP3342873B2 (es)
AT (1) ATE271606T1 (es)
AU (1) AU712585B2 (es)
CA (1) CA2214629C (es)
DE (1) DE69632949T2 (es)
ES (1) ES2225874T3 (es)
IL (1) IL117425A0 (es)
MX (1) MX9706827A (es)
WO (1) WO1996028548A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
AU3375199A (en) * 1998-04-01 1999-10-18 Genentech Inc. Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders
CZ20003767A3 (cs) * 1998-04-15 2002-01-16 Lexigen Pharmaceuticals Corp. Kompozice pro indukci imunitní odpovědi vůči zvolenému typu buňek v organismu savce a její pouľití pro výrobu léčiva
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
ES2571230T3 (es) * 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CZ20014123A3 (cs) * 1999-05-19 2002-06-12 Lexigen Pharmaceuticals Corp. Exprese a export interferonů-alfa jako Fc fúzních proteinů
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (ru) 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
CA2399832C (en) * 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
WO2001078778A1 (en) * 2000-04-13 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie (Vib) USE OF INHIBITION OF A Gas6 FUNCTION OR OF A Gas6 RECEPTOR FOR PREVENTING AND TREATING A CARDIOVASCULAR DISEASE
EP1199081A1 (en) * 2000-10-20 2002-04-24 Vlaams Interuniversitair Instituut voor Biotechnologie Use of inhibition of a growth arrest-specific gene (gas6) function or of a gas6 receptor for preventing and treating a thromboembolic disease
CA2412845C (en) * 2000-06-29 2014-07-22 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL206701B1 (pl) * 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2002090566A2 (en) * 2001-05-03 2002-11-14 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
GB2378899A (en) * 2001-08-25 2003-02-26 Thromb X N V Treatment of anemia
CA2469151C (en) 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20040157774A1 (en) * 2002-09-24 2004-08-12 Jing Yang Epitope-tagged recombinant Growth Arrest Specific Gene 6 protein
WO2004108748A2 (en) * 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
PT1572748E (pt) * 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
US20060183671A1 (en) * 2003-07-17 2006-08-17 Anne Angelillo-Scherrer Treatment of anemia
SI1698640T2 (sl) 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
AU2004309050B2 (en) * 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
DK1699821T3 (da) * 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
WO2005066348A2 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1819728B1 (en) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
US20100266604A1 (en) * 2007-11-09 2010-10-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
BRPI1016204A2 (pt) * 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
WO2012149018A1 (en) * 2011-04-25 2012-11-01 The Regents Of The University Of Colorado Mer tyrosine kinase inhibitors and methods of making and using the same
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2023212664A1 (en) * 2022-04-27 2023-11-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Synapse surgery tools and associated methods for neural circuit-specific synapse ablation and modification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585269A (en) * 1994-06-02 1996-12-17 The University Of North Carolina At Chapel Hill Isolated DNA encoding c-mer protooncogene
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells

Also Published As

Publication number Publication date
ES2225874T3 (es) 2005-03-16
EP0815224A1 (en) 1998-01-07
CA2214629A1 (en) 1996-09-19
DE69632949T2 (de) 2005-07-28
WO1996028548A1 (en) 1996-09-19
AU712585B2 (en) 1999-11-11
CA2214629C (en) 2001-07-10
JPH10505507A (ja) 1998-06-02
EP0815224B1 (en) 2004-07-21
AU5183696A (en) 1996-10-02
JP3342873B2 (ja) 2002-11-11
ATE271606T1 (de) 2004-08-15
US6169070B1 (en) 2001-01-02
IL117425A0 (en) 1996-07-23
DE69632949D1 (de) 2004-08-26

Similar Documents

Publication Publication Date Title
MX9706827A (es) Activacion de receptor por gas6.
AR020735A1 (es) Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas
ZA947825B (en) Stem cell proliferation factor.
DE69027990D1 (de) Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert
MXPA99007026A (es) Metodo para proliferacion y diferenciacion de celulas hematopoieticas y mesenquimatosas.
ES8700320A1 (es) Metodo de obtencion del exprimido de una materia seleccionada que contiene renina.
EP1650307A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
CA2171618A1 (en) Purine nucleoside phosphorylase gene therapy for human malignancy
NZ510356A (en) Molecules designated LDCAM
CA2079454A1 (en) Steroid 5.alpha.-reductases
ATE246251T1 (de) Verfahren zur herstellung von polypeptiden in surfaktinmutanten von bacillus zellen
DE69638077D1 (de) Bakterielle Produktion von Interferon-beta Polypeptiden
AU682140B2 (en) Multidrug resistance gene
ATE113982T1 (de) Verzweigungsenzym und dessen verwendung.
GB9811279D0 (en) Keratinocyte growth factor-2 products
WO2000036113A3 (en) Extending graft survival by heme oxygenase-i expression induced immunomodulation
GB9312315D0 (en) Leukocyte adhesion assay
IL154543A0 (en) The neurotrophic factor nnt-1
PL313257A1 (en) Novel tripeptides useful in treating immune system and central nervous system
PL314480A1 (en) Endothelin converting enzyme (ece)
IL105324A0 (en) Stem cell proliferation factor
DE59911877D1 (de) Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
NZ310563A (en) DNA encoding a porcine complement inhibitor
AU2099800A (en) Production of proteins